Skip to content

Treatment of COPD by Autologous Transplantation of Bronchial Basal Cells

Primary Research on Treatment of Chronic Obstructive Pulmonary Disease (COPD) by Transplantation of Autologous Bronchial Basal Cells

Status
UNKNOWN
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03156673
Enrollment
20
Registered
2017-05-17
Start date
2017-04-01
Completion date
2022-06-30
Last updated
2017-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Brief summary

Bronchial basal cells are proved to be able to regenerate lung structures to repair the injured lung. In COPD patients, bronchus structures are injured and cannot be repaired, which may result in the failure of pulmonary function rescue clinically.In our research, autologous bronchial basal cells will be transplanted into lung of patients suffered with COPD to treat the disease. Specifically, autologous bronchial basal cells will be dissected from brushed-off samples by bronchofiberscope. Then, they will be expanded in vitro and transplanted into lung to regenerate new alveoli and bronchus structures and re-establish pulmonary system.

Interventions

Patients will receive of clinical grade bronchial basal cells (BBCs) with a dosage of 10\^6 (1 million) cells/Kg/person via fiberoptic bronchoscopy after fully lavage of the localized lesions.

Sponsors

Regend Therapeutics
CollaboratorINDUSTRY
Tongji University
CollaboratorOTHER
First Affiliated Hospital of Shantou University Medical College
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
40 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Aged between 40 to 75; * Diagnosed with COPD according the guideline (a. with symptoms of productive cough, sputum production or shortness of breath; b. with poor airflow as indicated by FEV1\<70% predicted value and FEV1/FVC \< 0.7 in pulmonary function test; c. with exclusion of other pulmonary disease by CT or blood examination); * Clinically stable for more than 4 weeks; * Tolerant to bronchofiberscope; * Written informed consent signed.

Exclusion criteria

* Pregnant or lactating women; * Patients positive for syphilis, HIV; * Patients with malignant tumor; * Patients with serious or significant pulmonary infection and need anti-infection treatment; * Patients with serious heart disease(NYHA class Ⅲ-Ⅳ); * Patients with a history of abusing alcohol and illicit drug; * Patients participated in other clinical trials in the past 3 months; * Patients assessed as inappropriate to participate in this clinical trial by investigator.

Design outcomes

Primary

MeasureTime frameDescription
Forced expiratory volume in one second (FEV1)1-6 monthsAn indicator for pulmonary function test to assess airway obstruction
Forced vital capacity (FVC)1-6 monthsAn indicator for pulmonary function test to indicate the maximum amount of air a person can expel from the lungs after a maximum inhalation

Secondary

MeasureTime frameDescription
Maximum mid-expiratory flow (MMF)1-6 monthsAn indicator in pulmonary function test to stand for maximal (mid-)expiratory flow and is the peak of expiratory flow as taken from the flow-volume curve and measured in liters per second
Maximum voluntary ventilation (MVV)1-6 monthsAn indicator in pulmonary function test to measure the maximum amount of air that can be inhaled and exhaled within one minute
Diffusion capacity of CO (DLCO)1-6 monthsAn indicator for pulmonary function test to show the extent to which oxygen passes from the air sacs of the lungs into the blood
Modified medical research council (MMRC) chronic dyspnea scale1-6 monthsAn indicator to evaluate the level of dyspnea
St. George's respiratory questionnaire (SGRQ) scale1-6 monthsA questionnaire to assess life quality affected by the respiratory problems
6-minute-walk test (6MWT)1-6 monthsAn indicator to evaluate the exercise function of patients with moderate or severe pulmonary heart diseases
The ratio of forced expiratory volume in the first one second to the forced vital capacity (FEV1/FVC)1-6 monthsAn indicator in pulmonary function test to represent the proportion of a person's vital capacity that they are able to expire in the first second of forced expiration to the full vital capacity

Countries

China

Contacts

Primary ContactXiaohe Zheng, M.D.
70229120@qq.com086-0754-88258290
Backup ContactWei Zuo, Ph. D.
zuow@regend.cn

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026